Epidemiological association between uric acid concentration in plasma, lipoprotein(a), and the traditional lipid profile

Clinical Cardiology

Volumn 33, Issue 2, 2010, Pages

  Lippi, Giuseppe ^a   Montagnana, Martina ^a   Salvagno, Gian Luca ^a   Targher, Giovanni ^b   Guidi, Gian Cesare ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

Hyperglycemia; Hypertriglyceridemia; Lipoprotein(a); Uric acid

Indexed keywords

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; RISK FACTOR; SEX DIFFERENCE; URIC ACID BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHI-SQUARE DISTRIBUTION; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERURICEMIA; ITALY; LINEAR MODELS; LIPOPROTEIN(A); MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TRIGLYCERIDES; URIC ACID; YOUNG ADULT;

EID: 77649267050     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20511     Document Type: Article

References (39)

1. Giesecke D, Tiemeyer W. Defect of uric acid uptake in Dalmatian dog liver. Experientia. 1984;40:1415-1416.
2. Doumas BT, Hause LL, Simuncak DM, Breitenfeld D. Differences between values for plasma and serum in tests performed in the Ektachem 700 XR Analyzer, and evaluation of "plasma separator tubes (PST)." Clin Chem. 1989;35:151-153.
3. Ciuti R, Rinaldi G. Serum and plasma compared for use in 19 common chemical tests performed in the Hitachi 737 analyzer. Clin Chem. 1989;35:1562-1563.
4. Nath SD, Voruganti VS, Arar NH, et al. Genome scan for determinants of serum uric acid variability. J Am Soc Nephrol. 2007; 18:3156-3163.
5. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA. 2000; 283:2404-2410.
6. Forman JP, Choi H, Curhan GC. Plasma uric acid level and risk for incident hypertension among men. J Am Soc Nephrol. 2007;18: 287-292.
7. Chien KL, Chen MF, Hsu HC, et al. Plasma uric acid and the risk of type 2 diabetes in a Chinese community. Clin Chem. 2008;54: 310-316.
8. Gertler MM, Garn SM, Levine SA. Serum uric acid in relation to age and physique in health and in coronary heart disease. Ann Intern Med. 1951;34:1421-1431.
9. Kohn PM, Prozan GB. Hyperuricemia - relationship to hypercholesteremia and acute myocardial infarction. JAMA. 1959;170: 1909-1912.
10. Beard JT. Serum uric acid and coronary heart disease. Am Heart J. 1983;106:397-400.
11. Bickel C, Rupprecht HJ, Blankenberg S, et al. Serum uric acid as an independent predictor ofmortality in patients with angiographically proven coronary artery disease. Am J Cardiol. 2002;89:12-17.
12. Madsen TE, Muhlestein JB, Carlquist JF, et al. Serum uric acid independently predicts mortality in patients with significant, angiographically defined coronary disease. Am J Nephrol. 2005; 25:45-49.
13. Yoo TW, Sung KC, Shin HS, et al. Relationship between serum uric acid concentration and insulin resistance andmetabolic syndrome. Circ J. 2005;69:928-933.
14. Johnson RJ, Feig DI, Herrera-Acosta J, Kang DH. Resurrection of uric acid as a causal risk factor in essential hypertension. Hypertension. 2005;45:18-20.
15. Tuomilehto J, Zimmet P, Wolf E, Taylor R, Ram P, King H. Plasma uric acid level and its association with diabetes mellitus and some biologic parameters in a biracial population of Fiji. Am J Epidemiol. 1988;127:321-336.
16. Lippi G, Montagnana M, Franchini M, Favaloro EJ, Targher G. The paradoxical relationship between serum uric acid and cardiovascular disease. Clin Chim Acta. In press.
17. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem. 1972;18: 499-502.
18. Dobiasova M. Atherogenic index of plasma [log(triglycerides/ HDL-cholesterol)]: theoretical and practical implications. Clin Chem. 2004;50:1113-1115.
19. Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation. 1999;100:1481-1492.
20. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
21. Takahashi S, Yamamoto T, Moriwaki Y, Tsutsumi Z, Higashino K. Impaired lipoprotein metabolism in patients with primary gout - influence of alcohol intake and bodyweight. Br J Rheumatol. 1994;33:731-734.
22. Jiao S, Kameda K, Matsuzawa Y, Tarui S. Hyperlipoproteinaemia in primary gout: hyperlipoproteinaemic phenotype and influence of alcohol intake and obesity in Japan. Ann Rheum Dis. 1986; 45:308-313.
23. Gibson T, Grahame R. Gout and hyperlipidaemia. Ann Rheum Dis. 1974;33:298-303.
24. Naito HK, Mackenzie AH. Secondary hypertriglyceridemia and hyperlipoproteinemia in patients with primary symptomatic gout. Clin Chem. 1979;25:371-375.
25. Gibson T, Kilbourn K, Horner I, Simmonds HA. Mechanism and treatment of hypertriglyceridaemia in gout. Ann Rheum Dis. 1979; 3:31-35.
26. Cardona F, Tinahones FJ, Collantes E, Escudero A, Garcia-Fuentes E, Soriguer FJ. The elevated prevalence of apolipoprotein E2 in patients with gout is associated with reduced renal excretion of urates. Rheumatology. 2003;42:469-472.
27. Fox IH, John D, DeBruyne S, Dwosh I, Marliss EB. Hyperuricemia and hypertriglyceridemia: metabolic basis for the association. Metabolism. 1985;34:741-746.
28. Vuorinen-Markkola H, Yki-Järvinen H. Hyperuricemia and insulin resistance. J Clin Endocrinol Metab. 1994;78:25-29.
29. Rathmann W, Funkhouser E, Dyer AR, Roseman JM. Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA Study. Ann Epidemiol. 1998;8:250-261.
30. Clausen JO, Borch-Johnsen K, Ibsen H, Pedersen O. Analysis of the relationship between fasting serum uric acid and the insulin sensitivity index in a population-based sample of 380 young healthy Caucasians. Eur J Endocrinol. 1998;138:63-69.
31. Onat A, Uyarel H, Hergenç G, et al. Serum uric acid is a determinant ofmetabolic syndrome in a population-based study. Am J Hypertens. 2006;19:1055-1062.
32. Chu NF, Wang DJ, Liou SH, Shieh SM. Relationship between hyperuricemia and other cardiovascular disease risk factors among adult males in Taiwan. Eur J Epidemiol. 2000;16: 13-17.
33. Lin SD, Tsai DH, Hsu SR. Association between serum uric acid level and components of the metabolic syndrome. J Chin Med Assoc. 2006;69:512-516.
34. Klein R, Klein BE, Cornoni JC, et al. Serum uric acid. Its relationship to coronary heart disease risk factors and cardiovascular disease, Evans County, Georgia. Arch Intern Med. 1973; 132:401-410.
35. Collantes Estevéz E, Tinahones Madueño FJ, González Ruiz A, Añón Barbudo J, Pineda Priego M, Sánchez Guijo P. Renal excretion of urate by hyperuricaemic-hyperlipidemic patients. Clin Rheumatol. 1992;11:498-501.
36. Tinahones JF, Perez-Lindon G, Soriguer FJ, et al. Dietary alterations in plasma very low density lipoprotein levels modify renal excretion of urates in hyperuricemic-hypertriglyceridemic patients. J Clin Endocrinol Metab. 1997;82:1188-1191.
37. Takahashi S, Yamamoto T, Moriwaki Y, Tsutsumi Z, Higashino K. Increased concentrations of serum Lp(a) lipoprotein in patients with primary gout. Ann Rheum Dis. 1995;54:90-93.
38. Lippi G, Guidi G. Lipoprotein(a): an emerging cardiovascular risk factor. Crit Rev Clin Lab Sci. 2003;40:1-42.
39. Dawson J, Walters M. Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease? Br J Clin Pharmacol. 2006;62:633-664.